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PhosphorylationPTPRZ1–MET (ZM) proteins are a group of fusion proteins identiﬁed in human gliomas by
high-throughput transcriptome sequencing. ZM fusions are associated with poor prognosis in
afﬂicted glioma patients and mediate oncogenic effects in assays. In this study, we show that
ZM-carrying patients have increased hepatocyte growth factor receptor (MET) mRNA expression
levels induced by fusion with receptor-type tyrosine-protein phosphatase zeta (PTPRZ1).
Furthermore, ZM fusions preserve fundamental properties of wild-type MET with respect to process-
ing and dimerization, and enhance phosphorylation in an hepatocyte growth factor
(HGF)-dependent and independent manner. Our ﬁndings suggest that ZM induces gliomas through
elevated expression and phosphorylation of the MET oncoprotein.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The genomic landscape features many types of human cancers
with various alterations, including single nucleotide variations
(SNVs), insertions and deletions (InDels), gene ampliﬁcations and
translocations, which deregulate core cellular processes and sig-
naling pathways in tumor cells [1]. Translocations, which mayresult in fusion transcripts and produce abnormal novel proteins,
have been identiﬁed in almost every tumor type investigated, with
the majority of fusion events associated with hematological malig-
nancies [2,3]. However, with the advent of next generation
sequencing (NGS) technologies, increasing numbers of recurrent
fusion genes have been widely identiﬁed in solid tumors [4] as well
as tumor-derived cell lines [5]. Among the translocations identiﬁed
so far, many in-frame gene fusions obtain new oncogenic functions
and contribute to cancer development. Alternatively, with one of
the fusion partners being an oncogene, fusion leads to abnormal
activation of the oncogene by several mechanisms [6], including
fusing to a stronger promoter [7,8], deletion of a miRNA regulatory
region [9], or escaping degradation [10].
Glioma whole genome and transcriptome sequencing has
revealed a number of genomic rearrangements and fusion tran-
scripts involving receptor tyrosine kinases (RTKs). FGFR3-TACC3
was ﬁrst discovered in glioblastoma multiform (GBM) as an onco-
gene that induces constitutive kinase activity and triggers aneu-
ploidy [9,11]. The most frequent in-frame fusions in GBM involve
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genome and transcriptome sequencing [12,13]. For example,
EGFR-SEPT14 is a well-studied gene fusion that constitutively acti-
vates STAT3 signaling [13].
Although extensive cancer NGS translocations have been iden-
tiﬁed for many cancers, the GBM translocation landscape is poorly
understood. We examined 272 glioma patients at different patho-
logical stages, and detected 214 fusion transcripts, including 67
in-frame fusions. Of these, previously identiﬁed fusions, including
the recurrent FGFR3-TACC3 transcript, have also been detected in
three primary GBMs. It is noteworthy that four novel recurrent
RTK fusions of PTPRZ1–MET (ZM) have been identiﬁed in sequenc-
ing and validation cohorts, whereas the majority of fusions happen
in secondary GBMs (6/40, 15%) [14].
The MET kinase, also known as hepatocyte growth factor (HGF)
receptor, is a well characterized proto-oncogene that mediates
invasion and metastasis in various tumor types [15]. Many carcino-
mas involve MET aberrance such as mutation, ampliﬁcation, rear-
rangement, and transcriptional upregulation [16]. Data mining of
The Cancer Genome Atlas (TCGA) transcriptome data revealed
another ZM fusion in low-grade glioma [17]. Data suggest that
ZM fusion-harboring tumors exhibit a more aggressive phenotype
compared with ZM fusion-free ones. In addition, U87MG cells
expressing ZM show increased migratory activity by transwell
migration assay. Secondary GBM patients harboring ZM fusions
have signiﬁcantly compromised overall survival rates compared
with those free of ZM fusions [14].
Although ZM fusions are proved to be oncogenic in cell lines,
the molecular mechanisms underlining its oncogenicity motivated
our further investigation. In this study, we examined patient ZM
fusion RNA levels and examined dimerization and phosphorylation
in transfected HEK293 cells. Our ﬁndings show that ZM fusions are
activated by enhanced mRNA expression levels as well as highly
phosphorylated at the kinase domain, in an HGF-independent
manner.2. Materials and methods
2.1. Expression level analysis
Quantitation of mRNA expression was analyzed using the
Illumina HiSeq2000 transcriptome sequencing data of 272 grade
II–IV glioma samples from the Chinese Glioma Genome Atlas
(CGGA), under GEO accession number GSE48865. Expression anal-
ysis was performed using TCGA mRNA-seq pipeline for UNC data,
with modiﬁcations. First, clean reads were aligned to hg19 human
genome reference with MapSplice (v2.1.7) [18], followed by BAM
ﬁle sorting with SAMtools (v0.1.9) [19]. RSEM (v1.2.15) [20] was
then used to calculate sequencing read counts for each gene.
Expression data from different samples were normalized by the
Trimmed Mean of M values (TMM) method [21], and merged to
an FPKM (fragments per kilobase transcriptome per million frag-
ments) matrix for downstream analysis.2.2. Expression constructs
Full-length ZM fusions were ampliﬁed from glioma cDNA using
forward 50-ATGCGAATCCTAAAGCGTTTCCTCG-30 and reverse pri-
mers 50-TGATGTCTCCCAGAAGGAGGCTG-30 with Q5 DNA poly-
merase (New England Biolabs, Beverly, MA, USA). Wild-type MET
was ampliﬁed with a different forward 50-ATGAAGGCCCCCGCTGT
GC-30 but the same reverse primer 50-TGATGTCTCCCAGAAGGAGG
CTG-30. PCR products were puriﬁed using QIAquick PCR puriﬁca-
tion kit (Qiagen, Germantown, MD, USA) and cloned into 3FLAGCMV14 vector (Sigma–Aldrich, St. Louis, MO, USA) between
HindIII and KpnI cloning sites.
2.3. Cell culture and transfection
HEK293 cells were cultured with Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM, Life Technologies, Foster City, CA, USA) supple-
mented with 10% Fetal Bovine Serum (FBS, Life Technologies) at
37 C in a CO2 incubator. Cells were seeded in 6-well plates and
allowed to grow overnight to 60–80% conﬂuence. ZM fusion vec-
tors (2 lg) were individually mixed with 4-ll GenEscort II
(Wisegen, Nanjing, China), incubated for 15 min at room tempera-
ture, and added to the cell medium. CMV14 vector was used as a
control. Twenty-four hours after transfection, cells were collected
for analysis.
2.4. Immunoprecipitation and immunoblotting
Cells were harvested with IP buffer (0.5% Triton X-100, 20 mM
HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 2 mM EGTA, 10 mM
NaF, 2 mM DTT) together with PMSF and protease inhibitor cock-
tail (Sigma–Aldrich). After cell lysis and centrifugation, anti-FLAG
M2-beads (Sigma–Aldrich) were added to the supernatant and
incubated for 2 h. Beads were carefully washed 4 times with IP buf-
fer, boiled in SDS gel-loading buffer, and analyzed by immunoblot-
ting as described below.
For immunoblotting, 50-lg protein from whole cell lysates was
quantiﬁed by bicinchoninic acid (BCA) assay, and subjected to
SDS–PAGE separation. Resolved proteins were transferred to nitro-
cellulose membrane, probed with speciﬁc antibodies, and detected
by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Primary antibodies were FLAG (M2) mouse antibody (Sigma–
Aldrich), HA (F-7) mouse mAb (Santa Cruz Biotech, Dallas, TX,
USA), MET (25H2) mouse mAb and phospho-MET (Tyr1234/1235)
(D26) XP Rabbit mAb (both from Cell Signaling Technology,
Danvers, MA, USA), and phosphotyrosine (4G10) mouse mAb
(Merck Millipore, Billerica, MA, USA).
2.5. Crosslinking
Crosslinking studies were conducted as previously reported
[22], with modiﬁcations. Brieﬂy, cells were washed with cold PBS
then treated with 1 mM crosslinking reagent sulfo-EGS (Pierce)
for 2 h. After quenching with Tris buffer, cells were lysed and ana-
lyzed by western blotting.
2.6. Statistical analysis
Statistical analysis was performed with R (v3.0.3). A Wilcoxon
rank sum test was used to evaluate expression levels between
ZM fusions and ZM free subgroups. A two-tailed Student’s t-test
was used to evaluate expression and phosphorylation of WHO
grade II–IV gliomas.
3. Results
3.1. Enhanced MET RNA expression by fusion with PTPRZ1
PTPRZ1 encodes the receptor-type tyrosine-protein phos-
phatase zeta, which is tissue-speciﬁc and highly expressed in the
central nervous system (CNS) [23,24]. We performed scatter plot
analysis of TMM normalized expression levels of MET and
PTPRZ1 transcriptome sequencing data of 272 WHO grade II–IV
gliomas (Fig. 1A). Compared with PTPRZ1, MET FPKM values
appeared more diverse, ranging over nearly four orders of
Fig. 1. MET expression levels were enhanced in ZM fusions based on transcriptome sequencing. Expression levels are presented with FPKM values on log10 scales. (A) Scatter
plot of MET expression levels relative to that of PTPRZ1 from 272 WHO grade II–IV glioma samples. Red and gray dots indicate ZM-fusion and ZM-free samples, respectively.
(B) MET and (C) PTPRZ1 expression levels among grade II (n = 73), III (n = 100), and IV (n = 99) gliomas shown as boxplots. (D) Boxplots of PTPRZ1, MET, and HGF expression
levels between ZM-fusion (n = 3) and ZM-free (n = 96) grade IV samples.
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levels correlated with glioma grade [25,26]. In our sequencing
cohort, MET mRNA expression was statistically higher in WHO
grade IV gliomas (mean = 12.8, n = 99) compared with grade II
(mean = 2.0, n = 73, P value <0.001, two-tailed Student’s t test),
and grade III gliomas (mean = 3.1, n = 100, P value <0.01,
two-tailed Student’s t test) (Fig. 1B). We did not observe a differ-
ence in PTPRZ1 between grades II, III, and IV (means of grade II,
III, IV were equal to 505.3, 491.6 and 461.1, respectively, P value
>0.1, two-tailed Student’s t test) (Fig. 1C). To exclude expression
variation from different grades, we analyzed MET expression of
grade IV samples with and without ZM fusions (Fig. 1D). For sam-
ples afﬂicted with ZM fusions (n = 3, WHO grade IV), MET FPKM
values were elevated compared with ZM fusion-free samples
(n = 96, WHO grade IV, P-value <0.01, Wilcoxon rank sum test),
whereas PTPRZ1 and HGF FPKM values did not differ
(P-value = 0.2 and 0.4, respectively, Wilcoxon rank sum test).
These results suggest that the PTPRZ1 promoter drives stimulation
of MET mRNA, consistent with the fact that PTPRZ1 exhibits high
endogenous CNS expression. Another possibility for increased
MET expression is due to tandem duplication of the MET gene,
which may also cause the fusion event. The enhanced MET expres-
sion among patients with ZM fusions is consistent with overex-
pressed MET protein based on western blot results [14].
MET expression levels were previously shown to correlate with
glioma malignancy, as inhibition of MET and HGF leads to reducedtumor growth and tumorigenicity [27,28]. Enhanced MET expres-
sion in samples harboring ZM fusions might be a reason for shorter
overall clinical survival of these patients. However, considering the
possibility that enhanced ZM fusion is triggered by a strong PTPRZ1
promoter, it is important to test whether ZM fusions mediate onco-
genic functions similar to or more deleterious than those of MET.
3.2. Expression and processing of ZM fusions in HEK293 cells
To investigate expression and processing of ZM fusion proteins,
full-length ZM fusion constructs were expressed in HEK293 cells.
Given the novel N-terminus amino acids introduced to MET by
its fusion partner, it was not clear whether HGF binding afﬁnity
was affected. Therefore, we chose cell lines without detectable
HGF mRNA or protein to help clarify fundamental characteristics
of ZM proteins. HEK293 cell lysates expressing four fusion proteins
(ZM_E1–E2, ZM_E2–E2, ZM_E3–E2, ZM_E8–E2), with a C-terminal
FLAG-tag, were analyzed by SDS–PAGE and western blotting
(Fig. 2A). Western blot analysis of controls showed two MET bands,
consistent with previous studies [29]. The 170 and 140kDa bands
correspond to unprocessed MET precursors and the beta-chain of
mature MET, respectively. ZM fusions similarly expressed pro-
cessed 140 and 170kDa products, which were likely MET signal
peptide cleavage products (Fig. 2B). The ZM_E8–E2 construct con-
tained an additional 314 amino acids relative to wild-type MET,
leading to a 190kDa product corresponding to full-length fusion
Fig. 3. Homodimer and heterodimer ZM fusions formed in HEK293 cells. (A)
HEK293 expressing ZM-fusion proteins were exposed to crosslinking reagent sulfo-
EGS (1 mM) for 2 h. After quenching with Tris buffer, cells were lysed and
immunoblotted with FLAG antibody. (B) ZM-fusion FLAG tagged constructs were
individually co-transfected with a MET-HA tagged construct into HEK293 cells. Cell
lysates were immunoprecipitated and immunoblotted with either FLAG or HA
antibodies.
Fig. 2. ZM fusion proteins were processed by furin into mature MET. (A) Full-length ZM fusion and wild-type MET were ampliﬁed from tumor cDNA libraries, cloned into
3FLAG CMV14 vector, and transfected into HEK293 cells. Twenty-four hours after transfection, cells were collected for western analysis. Expression of ZM fusions was
detected using FLAG antibody. (B) Diagrammatic sketch of the ZM fusion constructs. The number indicates the length of the fusion protein or protein domains. Possible
cleavage sites of single peptide and MET processing marked with corresponding molecular weight from cleavage site to C-terminus. CA, alpha-carbonic anhydrase; SP, signal
peptide; TM, transmembrane domain; TK, tyrosine kinase. (C) After transfection, the furin inhibitor dec-RVKR-cmk was introduced into the cell medium at the indicated
concentrations. Proteins were expressed for 24 h, followed by western blot analysis.
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170kDa, while ZM_E1–E2 and ZM_E2–E2 added 24 and 46 amino
acids to MET, respectively, which were indistinguishable between
170kDa and full-length fusion proteins (only two bands were
detected).
It is well known that the MET Sema domain is processed into
alpha- and beta-subunits by the proprotein convertease furin
[29]. To further conﬁrm that the 140kDa band was processed
MET, we added the furin inhibitor dec-RVKR-cmk into culture
medium after transfection, at the indicated concentrations.
Dec-RVKR-cmk inhibited MET and ZM-fusion processing in a
dose-dependent manner. The 140kDa bands decreased as we
increased the concentration of dec-RVKR-cmk from 0 to 50 lM,
while full-length bands increased accordingly. Almost all pro-
cessed ZM_E2–E2 and ZM_E8–E2 were inhibited at 50 lM
(Fig. 2C). Inhibition assays conﬁrmed that the 140kDa band was
processed MET.
3.3. ZM fusions form homodimers and heterodimers with MET
Receptor tyrosine kinases, together with other families of cell
surface receptors, are activated by dimerization or oligomerization
[30]. Although it is well known that HGF binding is important for
MET dimerization, recent studies reveal that in many types of car-
cinomas that overexpress MET protein, MET is activated in a
ligand-independent manner [15,31]. The MET Sema domain is nec-
essary for its dimerization and downstream signaling both in
ligand-dependent and ligand-independent manners [22].
Since ZM fusions contain different length sequences, ranging
from dozens to hundreds amino acids added to the N-terminus
Sema domain, how dimerization is achieved between ZM fusions
is not obvious. Sulfo-EGS is a crosslinking reagent that is cell
impermeable and has been used to examine dimeric MET receptors
in the cell membrane [22]. We treated cells expressing ZM-fusion
Fig. 4. ZM fusions were highly phosphorylated in transfected HEK293 cells. (A) ZM-fusion constructs were transfected into HEK293 cells and whole cell lysates analyzed with
SDS–PAGE and immunoblotted with FLAG, MET, and p-MET (Y1234/Y1235) antibodies. (B) Phosphorylated-MET to MET ratio was quantiﬁed based on western blot results.
Data are normalized to the ratio of MET and shown as mean ± S.E.M. (n = 3). *P < 0.01, **P < 0.05 (two-tailed Student’s t test). (C) Whole cell lysates were immunoprecipitated
with FLAG antibody and immunoblotted with p-Tyr antibody. (D) Cells expressing ZM fusion and wild-type MET were stimulated with HGF (20 ng/ml) for 1 h.
Phosphorylation levels of ZM and MET were detected with FLAG and p-MET (Y1234/Y1235) antibodies.
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and western blot analysis. Interestingly, levels of processed MET
decreased in sulfo-EGS treated cells compared with those not
exposed, while the unprocessed band was not affected (Fig. 3A).
Meanwhile, a shifted band was detected at 280kDa in
cross-linked samples, corresponding to the dimeric form of pro-
cessed receptor. Both ZM fusion and wild-typeMET showed similar
patterns, indicating that processed ZM fusions and MET were pre-
sent as membrane-bound dimers.
To test whether ZM fusions heterodimerize with wild-type
MET, a FLAG-tagged ZM construct was co-transfected with a HA
tagged MET construct. A 140kDa band corresponding to a ZM–
MET heterodimer was detected by immunoprecipitation with
anti-FLAG M2 beads and immunoblotting with anti-HA antibody,
as well as by reverse immunoprecipitation with anti-HA beads
and immunoblotting with anti-FLAG antibody (Fig. 3B). In addition
to ZM–ZM homodimers, ZM–MET heterodimers have also been
observed. Since dimerization is crucial for MET activity, this sug-
gests that ZM fusion preserves receptor dimerization functionality,
without being affected by the sequence fused to the MET
N-terminus.3.4. ZM fusions display enhanced phosphorylation levels in the absence
of HGF
HGF, also known as scatter factor (SF), induces MET dimeriza-
tion and activation in an autocrine and paracrine manner [15].
Activated MET, in which the core kinase domain residues
Tyr1234 and Tyr1235 are phosphorylated, leads to
auto-phosphorylation of Tyr1349 and Tyr1356. Subsequently, sev-
eral cytoplasmic effector proteins, such as GAB1, GRB2, and PLC are
recruited to phosphorylated tyrosine at the carboxyl-terminus. It is
important to note that docking proteins attracted by GAB1,
together with MET binding proteins, activate downstream signal-
ing pathways [32].
It has been reported that without HGF stimulation, wild-type
MET phosphorylation is low [33]. Since HEK293 cells show nearly
undetectable HGF expression, it is reasonable to observe low MET
phosphorylation levels at Tyr1234 and Tyr1235 residues. ZM
fusion kinase domains were highly phosphorylated in HEK293 cells
(Fig. 4A). To compare the phosphorylation levels of MET and ZM
fusions, p-MET (Y1234/Y1235)/total-MET ratios were determined
by densitometric analysis of western blots. ZM_E1–E2, ZM_E2–E2
and ZM_E3–E2 displayed elevated phosphorylation levels com-
pared with wild-type MET (P < 0.01, 0.01 and 0.05, respectively,
two-tailed Student’s t test) (Fig. 4B), whereas ZM_E8–E2 phospho-
rylation was comparable with wild-type receptor. Phosphorylation
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FLAG antibody followed by immunoblotting with p-Tyr antibody
(Fig. 4C). These results suggest that ZM fusions are phosphorylated
in an HGF-independent manner. One possible explanation for the
highly phosphorylated ZM_E1–E2, ZM_E2–E2, and ZM_E3–E2 pro-
teins is that the peptide fused to the MET N-terminus functions as
HGF.
Human recombinant HGF (20 ng/ml) was added to cell culture
medium to test whether HGF activates ZM fusion proteins. After
treatment, both wild-type and ZM_E2–E2 fusion proteins showed
increased phosphorylation of the MET kinase domain (Fig. 4D).
This suggests that HGF interacts with ZM fusions to enhance phos-
phorylation. To better understand the precise mechanisms of HGF
and ZM interaction leading to enhanced phosphorylation, it will be
important to elucidate the crystal structure of ZM bound with HGF.
4. Discussion
We have previously shown that glioma ZM fusions mediate
oncogenic properties in U87MG cells, such as cell migration and
invasion [14]. To better understand the mechanism of oncogenic
growth, we analyzed ZM fusions at the transcription and protein
levels. First, transcriptome analyses implied that enhanced MET
expression is driven by the PTPRZ1 promoter, which increases
transcription of fused MET in the CNS. Glioma HGF expression with
and without ZM fusions suggests that enhanced MET expression
levels in ZM harboring gliomas is not related to HGF regulation.
Enhanced oncogene expression is mediated by its fusion partner,
as also observed with NPM-ALK [8], NFASC-NTRK1, and
BCAN-NTRK1 [34].
As a member of the receptor tyrosine kinase family, MET signal-
ing has been well-studied, with receptor dimerization and phos-
phorylation of Tyr1234/Tyr1235 being important for MET
activation [35]. Extensive analysis of MET-related gene fusions also
shows that dimerization and kinase domains are preserved during
fusion events. For example, TPR-MET [10] as well as several newly
identiﬁed MET-related fusions [17] lose the Sema domain respon-
sible for receptor dimerization. However, coiled–coil domains are
fused to truncated MET to mediate fusion protein dimerization.
We demonstrate that dimerization occurs as ZM–ZM homodimers
and ZM–MET heterodimers, preserving the full-length MET
sequence. In addition, we veriﬁed that ZM fusions possess charac-
teristics similar to wild-type MET, related to furin-mediated pro-
cessing. However, in the absence of HGF, ZM_E1–E2, ZM_E2–E2,
and ZM_E3–E2, fusion proteins are distinguishable from MET by
elevated phosphorylation levels. Therefore, our study provides evi-
dence that ZM fusions are phosphorylated in an HGF independent
manner. Together with our previous studies, this suggests that
enhanced MET expression and phosphorylation is induced by
fusion to PTPRZ1, which contributes to ZM oncogenic properties.
An increasing number of HGF–MET inhibitors have been devel-
oped for cancer therapy, which can be classiﬁed as extracellular
inhibitors of HGF–MET and MET kinase inhibitors [16,32,36].
Pharmaceutical companies have devoted great effort to evaluating
MET inhibitors in clinical studies [37]. Our previous results show
that overall survival of secondary GBM patients harboring ZM
fusions is signiﬁcantly decreased compared with secondary GBM
patients free of ZM fusions [14], suggesting that ZM fusions are a
potential drug target for a subset of glioma patients. We have so
far demonstrated that ZM fusions exhibit enhanced MET expres-
sion in tumor tissues and enhanced phosphorylation by cell assays.
Therefore, our current results may help to develop MET kinase
inhibitor therapy for secondary GBM patients harboring a ZM
fusion, and this therapy may also help patients showing elevated
MET kinase activity.Acknowledgments
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